About Cardax (OTCQB: CDXI)

Cardax devotes substantially all of its efforts to developing safe anti-inflammatory dietary supplements and drugs. Cardax is initially focusing on astaxanthin, which is a powerful and safe naturally occurring anti-inflammatory without the side effects of currently marketed anti-inflammatories.

Cardax recently launched its first commercial product, ZanthoSyn®, a safe anti-inflammatory for general health. ZanthoSyn® is a novel astaxanthin dietary supplement with superior absorption and purity, and is available through Cardax’s commercial website, www.zanthosyn.com.

Astaxanthin use is supported by hundreds of peer-reviewed papers published in leading medical research journals. More than 50 human clinical trials supporting the safety and efficacy of astaxanthin have been conducted to date. As the broader scientific community has discovered the health benefits of astaxanthin, awareness and demand for astaxanthin has grown dramatically.

Cardax management and Board have strong operational and technical expertise in healthcare product development and astaxanthin science.

Our patents protect compositions of matter, pharmaceutical compositions, and pharmaceutical uses of astaxanthin and related products in key disease areas.

The safety and efficacy of our product candidates have not been directly evaluated in clinical trials or confirmed by the FDA.